Marker Therapeutics appoints Katharine Knobil, M.D., to Board of Directors

Marker Therapeutics, Inc.

Appointment effective December 8, 2021; Dr. Knobil will serve until 2022 annual meeting.
Annual cash compensation of $40,000 paid quarterly; initial option for 125,000 shares vesting monthly over three years.
Dr. Knobil brings 20 years of leadership at GlaxoSmithKline; currently CMO at Agilent Technologies.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Katharine Knobil

Director

MRKR · Marker Therapeutics, Inc.

Effective: 2021-12-08
Filed: December 9, 2021, 6:59 PM ET

Effective December 8, 2021, the Board of Directors (the “ Board ”) of Marker Therapeutics, Inc. (the “ Company ”) appointed Katharine Knobil, M.D. as a member of the Board

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Katharine Knobil was appointed as Director at Marker Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

Effective December 8, 2021, the Board of Directors (the “ Board ”) of Marker Therapeutics, Inc. (the “ Company ”) appointed Katharine Knobil, M.D. as a member of the Board

View on SEC.gov

Marker Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-21-147884

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.